Computer–Guided Design and Evaluation of Some New Analogues of Glycogen Synthase Kinase-3 Inhibitors for The Treatment Of Alzheimer’s Disease
published by Aِl-Baath University
in 2016
in Pharmacy
and research's language is
العربية
Download
Abstract in English
Nowadays, glycogen synthase kinase 3 (GSK-3) inhibitors become
one of the most important drug targets for the development of their
selective inhibitors serving as promising drugs for the treatment of
many diseases, particularly Alzheimer's disease. Targeting GSK-3
enzyme has a therapeutic importance in many diseases and is one of
the valuable fields for researchers in both academic research centers
and pharmaceutical companies.
References used
Alonso, M. and A. Martinez, 2004, GSK-3 inhibitors: discoveries and developments. Curr Med Chem. 11(6): p. 755-63
De Ferrari, G.V. and N.C. Inestrosa, 2000, Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev. 33(1): p. 1-12
Vargas, J.Y., M. Fuenzalida, and N.C. Inestrosa, 2014, In vivo activation of Wnt signaling pathway enhances cognitive function of adult mice and reverses cognitive deficits in an Alzheimer's disease model. J Neurosci. 34(6): p. 2191-202